 Home > Active Ingredient News > Antitumor Therapy > Cancers: Long-term efficacy and safety of neoadjuvant chemotherapy and radiotherapy in patients with early breast cancer

Cancers: Long-term efficacy and safety of neoadjuvant chemotherapy and radiotherapy in patients with early breast cancer

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

beta glucan cancer

heliox 80 20

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The standard treatment for localized breast cancer is radiation therapy after lumpectomy, or total mastectomy when the tumor is too large for breast-conserving treatment

The standard treatment for localized breast cancer is radiation therapy after lumpectomy, or total mastectomy when the tumor is too large for breast-conserving therapy

From 2001 to 2003, 59 T2-3N0-2M0 invasive breast cancer (BC) patients who could not receive early breast-conserving therapy (BCS) were included in this prospective, non-randomized phase II study

The study population included women with an average age of 49 years [31-65], of which 41% were postmenopausal women

After 5 years of treatment, there was no grade 4 or grade 5 toxicity report, only one case of grade 3 adverse reaction was reported

Forty-one patients (69%) underwent breast-conserving surgery (BCS) and 18 patients underwent total mastectomy.

The 13-year overall survival rate was 70.

Overall survival rate

The 13-year metastasis-free survival rate was 71.

Metastasis-free survival

The local area control rate was 83.

Local area control rate

The median follow-up time was 13 years (3-18), and the local control rate was 92.

The median follow-up time was 13 years (3-18), and the local control rate was 92.
1% (95% CI: 83.
7-100)
.
A biopsy was done in every relapsed case
.
The initial lesion was grade 1, HR+, HER2-invasive ductal carcinoma
.
The median follow-up time was 13 years (3-18), and the local control rate was 92.
1% (95% CI: 83.
7-100)
.
A biopsy was done in every case of recurrence
.
The initial lesion was grade 1, HR+, HER2-invasive ductal carcinoma
.

Local control rate

In summary, studies have shown that neoadjuvant chemoradiotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions
.

In summary, studies have shown that neoadjuvant chemoradiotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions
.
Studies have shown that neoadjuvant radiotherapy and chemotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions
.
Studies have shown that neoadjuvant radiotherapy and chemotherapy for early breast cancer can achieve higher local control rates and limited adverse reactions
.

Original source:

Jornet, D.
; Loap, P.
; Pierga, J.
-Y.
; Laki, F.
; Vincent-Salomon, A.
; Kirova, YM; Fourquet, A.
Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long -Term Results of a Prospective Phase II Trial.
Cancers 2021, 13, 5107.
https://doi.
org/10.
3390/cancers13205107

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.